Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 17/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388878 | 0.95 | FGFR3 (0.71) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244362 | 0.90 | FGFR3 (0.62) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725922 | 0.88 | FGFR3 (0.64) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL18906134 | 0.84 | FGFR3 (0.92) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725870 | 0.84 | FGFR3 (0.90) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725961 | 0.84 | FGFR3 (0.91) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725881 | 0.83 | FGFR3 (0.92) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725872 | 0.82 | FGFR3 (0.61) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244632 | 0.82 | FGFR3 (0.71) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725963 | 0.82 | FGFR3 (0.71) | FGFR3KCNH2FGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885KCNH2 2907/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.